GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxurion NV (OTCPK:TBGNF) » Definitions » Total Liabilities

Oxurion NV (Oxurion NV) Total Liabilities : $21.52 Mil (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Oxurion NV Total Liabilities?

Oxurion NV's Total Liabilities for the quarter that ended in Dec. 2023 was $21.52 Mil.

Oxurion NV's quarterly Total Liabilities increased from Dec. 2022 ($17.56 Mil) to Jun. 2023 ($22.15 Mil) but then declined from Jun. 2023 ($22.15 Mil) to Dec. 2023 ($21.52 Mil).

Oxurion NV's annual Total Liabilities declined from Dec. 2021 ($22.58 Mil) to Dec. 2022 ($17.56 Mil) but then increased from Dec. 2022 ($17.56 Mil) to Dec. 2023 ($21.52 Mil).

Oxurion NV Total Liabilities Historical Data

The historical data trend for Oxurion NV's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxurion NV Total Liabilities Chart

Oxurion NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.03 11.24 22.58 17.56 21.52

Oxurion NV Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.58 15.18 17.56 22.15 21.52

Oxurion NV Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Oxurion NV's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=21.382+(0.128+-0.001000000000003
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0.013)
=21.52

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=7.143--14.379
=21.52

Oxurion NV's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=21.382+(0.128+-0.001000000000003
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0.013)
=21.52

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=7.143--14.379
=21.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oxurion NV Total Liabilities Related Terms

Thank you for viewing the detailed overview of Oxurion NV's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Oxurion NV (Oxurion NV) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxurion NV (OTCPK:TBGNF) » Definitions » Total Liabilities
Comparable Companies
XBRU:ACCB XBRU:INCLU XBRU:ZEN XBRU:MCC XBRU:BAS OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX ALNY OCSE:GMAB BGNE BMRN INCY
Traded in Other Exchanges
TG4:Germany OXUR:Belgium
Address
Gaston Geenslaan 1, Leuven, BEL, B-3001
Website
https://www.oxurion.com
Oxurion NV is a clinical stage biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME). The Group's research and development facilities are located in Belgium .The Company is engaged in the development of drugs to treat back-of-the-eye diseases, more specifically, ophthalmologic pharmaceuticals to treat vascular retinal disorders, specifically DME.